Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Santhera Pharmaceuticals

Healthcare

Sparks - Santhera Pharmaceuticals

More on this equity
Santhera Pharmaceuticals Holding (SIX: SANN) – FY24 results reflect AGAMREE’s strong market rollout
Published by Jyoti Prakash, CFA

Santhera Pharmaceuticals Holding has reported its full year 2024 results; a period marked by the launch and subsequent rollout of lead product AGAMREE for the treatment of Duchenne muscular dystrophy. Revenues of CHF39.1m were driven by product sales from launches in Germany and Austria, as well as in the US by licensing partner Catalyst. FY25 revenues are guided to be in the range of CHF65–70m, led by roll out in additional geographies (including the UK in Q225), with a steep ramp up to CHF150m by 2028 (excluding milestones). Cash balance of CHF41m at end-FY24 should provide a runway into mid-2026, by which time the company expects to break even. With the operating expense base (SG&A and R&D) guided to remain broadly stable (in the range of CHF 50–55m) for 2025 and beyond (on a constant portfolio basis), management anticipates a steady rise in margins over the next few years.

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

Morgan Advanced Materials (LSE: MGAM) – Phasing lifts H126 margin

TMT | Comment

Pathos Communications (AIM: NEWS) – Record July revenue supports H126 trading update

Industrials | Comment

PVA TePla (FRA: PVE) – Q226 results

Industrials | Comment

Metlen Energy & Metals (LSE: MTLN; ATHEX: MYTIL) – Strong H1; FY26 and medium-term guidance confirmed

Consumer | Comment

PZ Cussons (LSE: PZC) – FY26 results
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.